Pharma’s Out-licensed Drugs Spur Start-ups | Chemical & Engineering News
Volume 90 Issue 45 | p. 13 | Concentrates
Issue Date: November 5, 2012

Pharma’s Out-licensed Drugs Spur Start-ups

Department: Business
Keywords: pharmaceuticals, biotech, spin-offs

Amgen and venture capital firm Kleiner Perkins Caufield & Byers have launched Atara Biotherapeutics, which will focus on developing drugs for nephrology and oncology. Amgen is kicking in six assets in various stages of development, ranging from preclinical to Phase I studies, while KPCB will provide the initial funding for the start-up. In separate news, Puma Biotechnology raised $138 million in its initial public offering. The funds will support the development of neratinib, a breast cancer drug in late-stage testing that Puma licensed last year from Pfizer.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment